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Abstract
Background: Patients with inflammatory bowel disease (IBD) have a higher risk of developing opportunistic
infections due to either the disease itself or to treatment with immunosuppressants. This risk can be reduced
through vaccination. The aim of this study was to determine the prevalence of compliance with the guidelines on
recommended immunization schedule in patients with IBD in the health district of Lleida, Spain.
Methods: Descriptive, cross-sectional, retrospective study of data at December 31, 2016. The reference population
was formed by adults with a clinical diagnosis of IBD. The dependent variable was “compliance with the guidelines
on recommended immunization schedule”. Variables were sex, age, residence, diagnosis, vaccination against
measles, mumps, rubella, varicella, tetanus-diphtheria, influenza, pneumococcus, meningococcus C, hepatitis B, and
hepatitis A. Data were obtained from electronic medical records. For the data analysis, mean (standard deviation),
prevalence with 95% confidence intervals, χ2 test and Mann-Whitney test were used.
Results: Compliance did not exceed 65% for any of vaccines analysed in the 1722 studied patients with ulcerative
colitis or Crohn’s disease. Significant differences across age groups were found in compliance for measles, mumps,
rubella, varicella, tetanus, diphtheria and influenza in both ulcerative colitis and Crohn’s disease and for meningococcus
C and hepatitis A exclusively in ulcerative colitis.
Conclusions: Compliance in patients with IBD is low. Thus, prevention of immunopreventable diseases or their
complications is not maximized in this kind of patients. Greater awareness of how vaccines can reduce the risk of
vaccine-preventable infections is needed among both patients and healthcare professionals.
Keywords: Inflammatory bowel disease, Epidemiology, Immunization schedule, Public health
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: jsol.lleida.ics@gencat.cat
1Catalan Health Institute (ICS), Primary Care, Lleida, Spain
6Research Support Unit Lleida, Fundació Institut Universitari per a la recerca a
l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Lleida, Spain
Full list of author information is available at the end of the article
García-Serrano et al. BMC Public Health          (2020) 20:713 
https://doi.org/10.1186/s12889-020-08850-y
Background
Ulcerative colitis (UC) and Crohn’s disease (CD) are sub-
categories of inflammatory bowel disease (IBD) [1–3].
They constitute a chronic inflammatory condition that af-
fects the gastrointestinal tract and is caused by altered im-
mune responses against gut microbiota. Possible triggers
include diet, virus exposure, smoking, psychosocial stress,
and other factors that alter the pathogenesis of IBD [2, 3].
It generates high direct health costs associated with
hospitalization, surgery, pharmacological treatment, and
check-ups starting in the third year after diagnosis.
Hospitalization costs alone have been found to account
for 50 to 80% of all direct health costs [1].
Over 1.5 million individuals in North America and 2
million in Europe are estimated to have IBD [4]. The re-
ported prevalence in Spain is 205 cases per 100,000 in-
habitants [5], although the accuracy of estimates in
Europe is limited by small sample sizes. To address this
problem in Spain, a nationwide prospective population-
based cohort study known as EpidemIBD was launched
in 2017 to determine the true epidemiological scale of
IBD [6].
Recent years have seen an increase in the number of
IBD patients who need treatment with immunosuppres-
sive agents such as thiopurines (azathioprine, mercaptopu-
rine), methotrexate, calcineurin inhibitors (ciclosporin,
tacrolimus), biologics (infliximab, adalimumab), and corti-
costeroids (prednisolone or equivalent at a dose of ≥20mg
for at least 2 weeks) [7–9]. These patients are considered
to be immunosuppressed [1, 10, 11] and predisposed to a
higher risk of opportunistic infections [9], as evidenced by
numerous case reports and series [1, 7, 12, 13]. Treatment
with immunosuppressive agents has been associated with
a 3.9-fold increased risk for opportunistic infections in pa-
tients with IBD, with further analysis showing a 2.9-fold
increased risk for the use of any one agent and a 14.5-fold
increased risk for the use of two or three agents [7]. Op-
portunistic infections are frequently associated with sig-
nificant morbidity and mortality and may also result in
reduced treatment effectiveness [8, 9]. Patients at risk,
however, can be protected through vaccination [7, 14–18].
Several guidelines are available to support clinical practice,
including a 2010 practical guide to vaccinate patients with
IBD [17] and recommendations from working groups
such as the Spanish Society of Preventive Medicine, Public
Health, and Hygiene [18] and the European Crohn’s and
Colitis Organisation [11]. The vaccination manual of the
Catalan Public Health Agency did not include a specific
section devoted to the vaccination of patients with IBD
until 2018 [19].
Evidence on the immunogenicity and safety of vac-
cines in treated patients with IBD is still limited, as dif-
ferent immunomodulators can alter immune responses
to vaccines [7, 11, 15]. According to some studies,
patients with IBD had lower antibody responses after
hepatitis B vaccination than the general population
[7, 20, 21]. In other studies, IBD patients under
treatment with infliximab and immunomodulatory ther-
apy showed an impaired response to a single dose of triva-
lent inactivated influenza vaccine [22, 23]. For this reason,
and due to their increased risk of opportunistic infections
in the first year of immunosuppressive therapy, IBD pa-
tients should be vaccinated as soon as possible after diag-
nosis [1, 15, 24, 25]. Prevention of infectious disease in
this population is a public health issue and vaccination
may be an effective tool.
In the sanitary region of Lleida, Spain, IBD patients
are prescribed biologics and monitored in specialist care
settings, but vaccines are routinely administered in pri-
mary care and recorded in a centralized electronic data-
base. Although the access to vaccination is free and
universal in Spain and many infections can be prevented
by vaccination, coverage in clinical practice remains un-
certain. Better communication between practitioners
working at different levels of care is essential to prevent
under-recording and under-immunization [1, 25].
This study represented the first step towards optimal
vaccination coverage, and aimed to determine the pro-
portion of IBD patients who have been appropriately
vaccinated according to the recommended
immunization schedule in the health district of Lleida,
Spain.
Methods
Aim
The aim of this study was to determine the proportion
of IBD patients who have been appropriately vaccinated
according to the recommended immunization schedule
in the health district of Lleida, Spain in order to settle
the basis for a future intervention in both primary care
and hospitals to reach a better compliance of these
patients.
Study design and setting, data collection and information
sources
Retrospective, cross-sectional descriptive analysis of data
from the Catalan Health Institute’s ECAP database. Re-
cords introduced in the database until December 31,
2016 corresponding to all the eligible patients assigned
to a primary care unit in the health district of Lleida,
Spain were obtained.
ECAP database was fully implemented in all Lleida pri-
mary care settings in 2005, but records collected in
physical format before implementation were introduced
in the database between 1998 and 2005. This database is
routinely used by all primary care practitioners to collect
electronic medical records from the patients, including
administrative data, medical conditions, vaccinations,
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prescriptions and laboratory results, as well as diagnosis
associated with hospital and outpatient visits, attended
by the Catalan primary public healthcare system.
Reference and study population
The reference population was formed by adults with
IBD in the healthcare district of Lleida. To be included,
patients had to have a clinical diagnosis of UC or CD, be
18 years or older, and be assigned to a primary care unit
in the sanitary district of Lleida. In order to focus the
study on the immunization that depended directly on
the health system, patients with a history of an allergic
reaction to a vaccine or to any component of a vaccine
needed to achieve adequate immunization were ex-
cluded, as were seronegative patients who had refused to
be vaccinated.
Variables
The dependent variable was “compliance with the guide-
lines on recommended immunization schedule”, from
now on “compliance” (yes/no), which was assessed ac-
cording to compliance with vaccination dosing and
schedule recommendations for the disease in question
(UC or CD), immunosuppression status, and serology
results [26, 27] (Table 1). The above information was en-
tered into a purpose-designed algorithm applied to each
patient to determine whether or not they were ad-
equately immunized.
The independent variables were sex, age, area of resi-
dence (rural vs. urban), diagnosis (CD or UC), and pri-
movaccination against measles, mumps, and rubella
(MMR), varicella, tetanus-diphtheria, influenza, pneumo-
coccus, meningococcus C, hepatitis B, and hepatitis A
[26, 27].
Statistical analysis
Quantitative variables were expressed as mean and
standard deviation (SD) and qualitative variables as per-
centages. Prevalence estimates were presented with 95%
confidence intervals. Differences between compliance
rates according to the study variables were analysed
using the χ2 or Mann-Whitney test as appropriate. Stat-
istical significance was established at a p value < 0.05.
Table 1 Criteria to assess compliance
Infections Identifying events
(at least one of the following criteria should be met)
Measles, mumps and
rubella
Date of birth before January 01, 1966
History of measles, mumps, rubella
Record of seropositivity for all three diseases: measles IgG level > 16.5 IU/mL; mumpsIgGlevel11 IU/mL, rubella IgG level > 15
IU/mL
Record of two MMR vaccine doses administered at least 1 month apart
Varicella History of varicella
Record of seropositivity for varicella zoster virus: IgG level > 165 IU/mL
Record of two varicella vaccine doses administered at least 1 month apart
Tetanus Record of at least five doses of tetanus toxoid vaccine administered before the age of 16 years
Record of at least three doses of tetanus toxoid vaccine administered at a minimum interval of 0–1-6 months after the age
of 7 years
Influenza Record of influenza vaccine administration: high-dose seasonal influenza vaccine for patients aged > 60 or > 65 years or
standard influenza vaccine for other patients
Pneumococcus Record of one dose of 13-valent pneumococcal conjugate vaccine (PCV13) and one dose of pneumococcal polysaccharide
vaccine (PPSV23) administered at least 2 months apart
Record of one dose of PCV13 and one dose of PPSV23 administered at least 12 months apart
Record of at least one dose of PCV13 administered in the past year
Record of at least one dose of PPSV23 administered in the past year
Meningococcus C Record of at least one dose of meningococcal vaccine administered after 12 months of age
Hepatitis B History of hepatitis B and record of seropositivity for hepatitis B surface antigen (HBsAg) > 0.9 IU/mL; total antibodies (anti-
HBc) > 0.9 IU/mL
Post-vaccine record of seropositivity for anti-HBs > 12 IU/mLa
Record of three doses of hepatitis B vaccine administered at a minimum interval of 0–1-6 months
Record of four doses of hepatitis B vaccine administered at a minimum interval of 0–1–2-6 months
Record of three doses of hepatitis A + B vaccine administered at a minimum interval of 0–1-6 months
Hepatitis A History of hepatitis A
Record of seropositivity: IgG level > 40 IU/mL
Record of two doses of monovalent vaccine administered at least 6 months apart
Record of three doses of combined hepatitis A + B vaccine administered at a minimum interval of 0–1-6 months.
IgG immunoglobulin G
aAccording to laboratory criteria of the health district of Lleida, Spain
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Results
In total, 1722 patients were studied: 1420 (82.5%) had
UC and 302 (17.5%) had CD. Patients with UC had a
mean (SD) age of 54.6 (18.8) years, with an age range
from 18 to 97, 50.8% were women, and 66.4% lived in a
rural area. Those with CD had a mean (SD) age of 47.8
(16.6) years, with an age range from 18 to 96, 44.7%
were women, and 63.9% lived in a rural area (Table 2).
Compliance did not exceed 65% in any of the two dis-
eases. Significant differences in compliance for all the
studied vaccines except for MMR were observed be-
tween patients with UC and CD, with higher rates in CD
except for vaccination against influenza (Table 3). Cause
of compliance (vaccination or natural immunity) is spe-
cified in the Supplementary table.
Significant differences between age groups were found
in compliance for MMR, varicella, tetanus, diphtheria
and influenza in both UC and CD (Table 4, Table 5),
and for meningococcus C and hepatitis A exclusively in
UC (Table 5). Compliances for MMR and seasonal influ-
enza among patients with UC or CD were associated to
higher age groups (Table 4, Table 5).
Discussion
IBD is associated with high morbidity and premature
death, and represents a high financial burden in the
form of direct costs (e.g., hospitalization, treatment,
check-ups), indirect costs (e.g., productivity loss and dis-
ability), and intangible costs (e.g., loss of quality of life)
[1]. Furthermore, patients diagnosed with IBD are at
higher risk of suffering opportunistic infections [9, 15,
28, 29] and at the same time, of a higher severity of
these infections [8, 29]. Most of these opportunistic in-
fections are preventable with adequate vaccination ac-
cording to underlying pathology [8, 10, 15, 24], for this
reason, vaccination regardless of age against measles,
mumps, rubella, varicella, tetanus and diphtheria,
pneumococcus and influenza is recommended [26, 27].
The low compliance rates in patients with IBD observed
in our study, added to the reported or disputed alter-
ation of immunogenicity of vaccines in this kind of pa-
tients [8, 10, 23, 30] implies a public health problem that
must be taken into account in order to look for im-
provement strategies.
Latest official data regarding seasonal influenza vaccin-
ation coverage in the Catalan population aged 60 years
or older reported a coverage of 47.7% [31]. In 2016–
2017, a vaccination coverage of 54.3% was reported for
population aged 65 years or older [32]. In our study, we
observe coverage rates for seasonal influenza of more
than 70% in patients aged 61 years or older. However,
these rates decrease to nearly zero in younger groups,
suggesting that patients would have been recruited for
vaccination according to seasonal campaigns aimed to
aged population rather than according to their specific
risk group. This possibility is supported by the findings
of a Spanish study on pneumococcal vaccination cover-
age, which found higher uptake in patients for whom
routine vaccination was indicated (generally older
adults), regardless of their risk profile [33]. Similarly, the
high tetanus-diphtheria compliance observed in our
series could be due to the inclusion of these vaccines in
routine vaccination programs.
Vaccination against varicella has been recommended
for all immunocompromised seronegative patients with
IBD [8, 10, 15], and although seroprevalence against
varicella in Spain is estimated to be around 93% [34],
seronegative patients must be detected and vaccinated in
order to assure adequate immunization. Thus, the low
Table 2 Sociodemographic characteristics, patients with
ulcerative colitis and Crohn’s disease, sanitary district of Lleida
(Spain) 2016
Ulcerative colitis
No. (%)
Crohn’s disease
No. (%)
P Value
No. of patients 1420 302
Sex (female) 721 (50.8%) 135 (44.7%) 0.064
Rural area (yes) 943 (66.4%) 193 (63.9%) 0.444
Age (SD), y 54.6 (18.8) 47.8 (16.6) < 0.001
Table 3 Compliance in patients with ulcerative colitis and Crohn’s disease, sanitary district of Lleida (Spain) 2016
Infections Ulcerative colitis
No. (%) (95% CI)
Crohn’s disease
No. (%) (95% CI)
P value
Measles, mumps, rubella 912 (64.2%) (61.7–66.7) 177 (58.6%) (52.8–64.2) 0.076
Varicella 335 (23.6%) (21.4–25.8) 134 (44.4%) (38.8–50.0) < 0.001
Tetanus-diphtheria 391 (27.5%) (25.2–29.9) 121 (40.1%) (34.5–45.6) < 0.001
Influenza 386 (27.2%) (24.9–29.5) 45 (14.9%) (10.9–18.9) < 0.001
Pneumococcus 96 (6.8%) (5.5–8.1) 58 (19.2%) (14.8–23.6) < 0.001
Meningococcus C 111 (7.8%) (6.4–9.2) 71 (23.5%) (18.7–28.3) < 0.001
Hepatitis B 99 (7%) (5.6–8.3) 69 (22.8%) (18.1–27.6) < 0.001
Hepatitis A 27 (1.9%) (1.2–2.6) 14 (4.6%) (2.3–7.0) 0.009
CI Confidence interval
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compliance observed for varicella vaccination in our
series is worrying, especially because of its risk of com-
plication to herpes zoster at adult age, which is higher in
immunosuppressed patients, and particularly in those re-
ceiving immunosupressive therapy [15, 35]. However,
vaccination for varicella is contraindicated in patients
already on immunosuppressive therapy due to the in-
creased risk of herpes zoster infection [10, 15, 28]. Thus,
it is important, if possible, to vaccinate before initiation
of therapy and to ensure that cohabitants of IBD patients
are protected against this disease [10, 15, 19].
Hepatitis B compliance is highest in patients aged be-
tween 41 and 60 years but overall compliance is low.
Other authors have reported low response rates to hepa-
titis B vaccine in patients with IBD, particularly in those
on immunosuppressive therapy and with active disease
[36], resulting in inadequate hepatitis B surface antibody
levels in 70% of vaccinated patients [5]. In this sense,
vaccination during remission or periods of adequate im-
mune function has been recommended [1, 8, 15, 36].
The present study shows that compliance is better in
patients with CD for all diseases except for MMR and
influenza, these two latter cases because of the higher
proportion of older patients in UC. Other authors have
associated disease severity to higher adherence to treat-
ment [37]. In this line, we hypothesize that disease sever-
ity, added to the higher risk for opportunistic infections
of CD compared to UC patients [8], could also be asso-
ciated to the higher compliance due to the higher aware-
ness of both patients and practitioners about their
condition. However, compliance is low, and does not ex-
ceed 65% for any of the vaccines analysed. This observa-
tion coincides with the findings of several authors, who
have reported suboptimal coverage levels in both pri-
mary care and hospital settings [15, 25, 38].
In the sanitary district of Lleida most patients with
IBD are diagnosed in hospital settings, but vaccines are
mainly administered by primary care practitioners and
records are kept in the centralized ECAP database.
Sometimes, patients do not visit their primary care
centre for vaccination, and in other cases, insufficient or
confusing information regarding their health status or
their treatment is provided: approximately 50% of pa-
tients with IBD do not know that they need to be vacci-
nated against certain diseases [25]. This lack of
awareness, together with other barriers that complicate
compliance such as vaccination costs and incorrect or
Table 4 Compliance by age in patients with Crohn’s disease, sanitary district of Lleida (Spain) 2016
Infections ≤ 40 y
(n = 114)
41–60 y
(n = 127)
≥ 61 y
(n = 61)
Total
(n = 302)
P value
No. (%) (95% CI) No. (%) (95% CI) No. (%) (95% CI) No. (%) (95% CI)
Measles, mumps, rubella 30 (26.3%) (18.2–4.4) 86 (67.7%) (58.8–75.7) 61 (100%) (94.1–100) 177 (58.6%) (52.8–64.2) < 0.001
Varicella 60 (52.6%) (43.5–61.8) 55 (43.3%) (34.7–51.9) 19 (31.1%) (19.5–42.8) 134 (44.4%) (38.8–50.0) 0.006
Tetanus and diphtheria 35 (30.7%) (22.2–39.2) 57 (44.9%) (36.2–53.5) 29 (47.5%) (35.0–60.1) 121 (40.1%) (34.5–45.6) 0.016
Influenza 1 (0.9%) (0.0–2.6) 0 (0%) (0.0–0.0) 44 (72.1%) (60.9–83.4) 45 (14.9%) (10.9–18.9) < 0.001
Pneumococcus 19 (16.7%) (9.8–23.5) 27 (21.3%) (14.4–28.4) 12 (19.7%) (9.7–29.6) 58 (19.2%) (14.8–23.6) 0.531
Meningococcus C 24 (21.1%) (13.6–28.5) 37 (29.1%) (21.2–37.0) 10 (16.4%) (7.1–25.7) 71 (23.5%) (18.7–28.3) 0.778
Hepatitis B 19 (16.7%) (9.8–23.5) 35 (27.6%) (19.8–35.3) 15 (24.6%) (13.8–35.4) 69 (22.8%) (18.1–27.6) 0.134
Hepatitis A 8 (7%) (2.3–11.7) 5 (3.9%) (0.6–7.3) 1 (1.6%) (0.0–4.8) 14 (4.6%) (2.3–7.0) 0.094
CI Confidence interval.
Table 5 Compliance by age group in patients with ulcerative colitis, sanitary district of Lleida (Spain) 2016
Infections ≤ 40 y
(n = 377)
41–60 y
(n = 511)
≥ 61 y
(n = 532)
Total
(n = 1420)
P value
No. (%) (95% CI) No. (%) (95% CI) No. (%) (95% CI) No. (%) (95% CI)
Measles, mumps, rubella 60 (15.9%) (12.2–19.6) 320 (62.6%) (58.3–66.8) 532 (100%) (99.3–100) 912 (64.2%) (61.7–66.7) < 0.001
Varicella 136 (36.1%) (31.2–40.9) 147 (28.8%) (12.2–19.6) 52 (9.8%) (7.2–12.3) 335 (23.6%) (21.4–25.8) < 0.001
Tetanus-diphtheria 61 (16.2%) (12.5–19.9) 152 (29.7%) (25.8–33.7) 178 (33.5%) (29.4–37.5) 391 (27.5%) (25.2–29.9) < 0.001
Influenza 1 (0.3%) (0.0–0.8) 7 (1.4%) (0.4–2.4) 378 (71.1%) (67.2–74.9) 386 (27.2%) (24.9–29.5) < 0.001
Pneumococcus 21 (5.6%) (3.3–7.9) 36 (7%) (4.8–9.3) 39 (7.3%) (5.1–9.5) 96 (6.8%) (5.5–8.1) 0.316
Meningococcus C 35 (9.3%) (6.4–12.2) 55 (10.8%) (8.1–13.5%) 21 (3.9%) (2.3–5.6%) 111 (7.8%) (6.4–9.2%) 0.001
Hepatitis B 19 (5%) (2.8–7.2%) 56 (11%) (8.3–13.7) 24 (4.5%) (2.7–6.3) 99 (7%) (5.6–8.3) 0.445
Hepatitis A 14 (3.7%) (1.8–5.6) 12 (2.3%) (1.0–3.7) 1 (0.2%) (0.0–0.6) 27 (1.9%) (1.2–2.6) < 0.001
CI Confidence interval.
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inadequate vaccination recommendations by healthcare
professionals, must be addressed [25, 39].
Interventions involving patient education and continu-
ous training for healthcare professionals are needed to
improve compliance among IBD patients [7, 17, 25, 40],
and standardized vaccination protocols are therefore es-
sential for reducing vaccine-preventable infections and
improving patient quality of life. In this sense, in 2018
the Spanish Ministry of Health, Consumption, and Social
Wellbeing published vaccination recommendations for
patients of all ages at risk of vaccine-preventable dis-
eases, which included specific protocols for IBD [41].
Furthermore, several authors have proposed using online
systems to facilitate coordination between professionals
working at different levels of care [1, 25]. Options in-
clude the use of electronic devices, electronic reminders
for both patients and healthcare professionals, and pop-
up checklists. In one study, an automatic computer vac-
cination reminder system for patients under treatment
with infliximab led to higher uptake rates [25].
The observed low compliance is a public health issue
in the studied health district, and according to the com-
mented recommendations, several actions that could in-
crease compliance have been proposed and are already
being implemented. These actions include continuous
professional development programs for healthcare pro-
fessionals, online meetings with regional vaccination
managers and implementation of telematics, online and
other systems to improve communication between dif-
ferent levels of care. A connection between ECAP data-
base and hospital software that updates all relevant
information such as vaccines has been required to the
database managers.
Our study has some limitations. As our findings are
based on a retrospective review of data from the ECAP
database, they may be subject to information bias in the
form of incomplete or missing data on vaccinations,
diagnoses, and analysis results. Incomplete records could
be aggravated because of the different databases used in
primary care respect to hospital services, as well as the
impossibility of access to private care databases. For this
reason, and although most of the patients are attended
in the public health services, a uniform database con-
taining data from all the mentioned sources is essential
to obtain more reliable data. Nevertheless, these missing
records would also be found in daily practice, and com-
pliance was determined the same way as it would have
been in clinical practice, so all the ECAP records were
carefully analysed to minimize the risk of information
bias. Because of the difficulty of defining immunosup-
pression in a cross-sectional study, this study did not in-
clude data regarding immunosuppressive medication, so
another limitation is that we were not able to discern be-
tween immunosuppressed and non immunosuppressed
patients. We expect to dispose of this data in further
studies.
Conclusions
Compliance with the guidelines of the recommended
vaccination schedule in patients with IBD is low. Thus,
prevention of immunopreventable diseases or their com-
plications is not maximized in this kind of patients.
Awareness about the need for vaccination in patients
with IBD must also be improved among both patients
and healthcare professionals, as immune responses can
be impaired by the disease itself and the use of immuno-
suppressive therapy. We propose to unify electronic
health records between primary care and hospital set-
tings by creating efficient communication and warning
systems. Efficiency and safety in clinical practice and
control of pathologies would be maximized if this data-
base also included information from private care and
other relevant instances. It would be interesting to con-
duct follow-up studies to determine the incidence of
complications in unvaccinated patients that could have
been prevented through vaccination.
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